DCT

3:23-cv-01876

Arbutus Pharma Corp v. Pfizer Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 3:23-cv-01876, D.N.J., 04/04/2023
  • Venue Allegations: Venue is alleged to be proper for Pfizer due to its commission of infringing acts and its regular and established place of business in the District of New Jersey. Venue is alleged to be proper for BioNTech because it is subject to personal jurisdiction in the district.
  • Core Dispute: Plaintiffs allege that Defendants' COVID-19 mRNA vaccine, Comirnaty, infringes five U.S. patents related to lipid nanoparticle (LNP) compositions and the methods and apparatus for their manufacture.
  • Technical Context: The lawsuit centers on lipid nanoparticle technology, a critical drug delivery system that protects fragile messenger RNA (mRNA) molecules and enables their entry into human cells, which was foundational to the rapid development of mRNA-based vaccines.
  • Key Procedural History: The complaint alleges that Defendant BioNTech was aware of Plaintiffs' patents and technology at least as of July 2018, when it signed a license agreement with Plaintiff Genevant to use the LNP technology for applications in cancer and rare liver disease, but not for infectious diseases. Plaintiffs also allege sending multiple notice letters to Defendants regarding potential infringement beginning in November 2020, prior to the vaccine's emergency use authorization.

Case Timeline

Date Event
2002-06-28 Priority Date for '651, '320, and '098 Patents
2008-04-15 Priority Date for '359 and '378 Patents
2013-07-23 '359 Patent Issued
2016-11-29 '651 Patent Issued
2018-07-04 BioNTech signs license agreement with Genevant
2020-03-17 Pfizer and BioNTech announce collaboration agreement
2020-11-23 Plaintiffs notify Defendants of potential infringement of '651 and '359 Patents
2020-12-11 FDA grants Emergency Use Authorization for Accused Product
2021-08-23 FDA approves Biologics License Application for Accused Product
2021-10-12 '378 Patent Issued; Plaintiffs notify Defendants of potential infringement
2022-04-12 '320 Patent Issued
2022-05-03 '098 Patent Issued
2022-06-03 Plaintiffs notify Defendants of potential infringement of '320 and '098 Patents
2023-04-04 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,504,651 - "Lipid Compositions for Nucleic Acid Delivery," issued November 29, 2016

The Invention Explained

  • Problem Addressed: The patent addresses the long-standing challenge of delivering fragile therapeutic nucleic acids, such as RNA, into cells within a living organism Compl. ¶¶33-34 Without a suitable delivery vehicle, these molecules are quickly degraded in the body and cannot cross cell membranes to reach their intracellular targets, rendering them ineffective Compl. ¶33
  • The Patented Solution: The invention provides a lipid-based particle formulation designed to encapsulate and protect messenger RNA (mRNA). The formulation comprises a plurality of lipid vesicles, with each vesicle composed of a specific combination of a cationic lipid, an amphipathic lipid, and a polyethyleneglycol (PEG)-lipid Compl. ¶70 This structure shields the mRNA from degradation during its journey through the bloodstream and facilitates its entry into a target cell Compl. ¶4 The patent specifies that a high percentage of the mRNA must be "fully encapsulated" within these vesicles to ensure effective delivery '651 Patent, cl. 1
  • Technical Importance: This technology provided a viable solution to the "delivery problem" that had stymied the field of RNA-based medicine for decades, making therapies and vaccines based on mRNA a practical possibility Compl. ¶4 Compl. ¶¶34-37

Key Claims at a Glance

  • The complaint asserts infringement of at least Claim 1 Compl. ¶70
  • The essential elements of independent Claim 1 are:
    • A lipid vesicle formulation comprising: (a) a plurality of lipid vesicles, wherein each lipid vesicle comprises a cationic lipid, an amphipathic lipid, and a polyethyleneglycol (PEG)-lipid; and
    • (b) messenger RNA (mRNA);
    • wherein at least 70% of the mRNA in the formulation is fully encapsulated in the lipid vesicles.
  • The complaint notes that Claim 9, which depends on Claim 1, specifies that each lipid vesicle is a lipid-nucleic acid particle Compl. ¶70

U.S. Patent No. 8,492,359 - "Lipid Formulations for Nucleic Acid Delivery," issued July 23, 2013

The Invention Explained

  • Problem Addressed: The patent background describes the need for a safe and effective non-viral system for systemic nucleic acid delivery, noting that previous systems were often toxic, inefficient, or rapidly cleared from circulation, limiting their therapeutic utility '359 Patent, col. 1:19-44
  • The Patented Solution: The invention discloses a specific "recipe" for a nucleic acid-lipid particle, defining the composition by the molar percentages of its constituent lipids. The claimed particle comprises a nucleic acid, a cationic lipid, a non-cationic lipid (itself a mixture of a phospholipid and cholesterol in specific proportions), and a conjugated lipid that prevents particle aggregation, all within defined molar ratio ranges '359 Patent, cl. 1 This specific formulation, referred to in the specification as the "1:57 formulation," is designed to create small, stable, serum-resistant particles suitable for systemic delivery '359 Patent, col. 4:1-13
  • Technical Importance: By defining a precise and stable lipid formulation with specific component ratios, the invention provided a reproducible platform for creating effective LNP-based drug delivery systems Compl. ¶¶37-38

Key Claims at a Glance

  • The complaint asserts infringement of at least Claim 1 Compl. ¶87
  • The essential elements of independent Claim 1 are:
    • A nucleic acid-lipid particle comprising: (a) a nucleic acid;
    • (b) a cationic lipid comprising from 50 mol % to 65 mol % of the total lipid present in the particle;
    • (c) a non-cationic lipid comprising a mixture of a phospholipid (from 3 mol % to 15 mol %) and cholesterol (from 30 mol % to 40 mol %); and
    • (d) a conjugated lipid that inhibits aggregation of particles (from 0.5 mol % to 2 mol %).
  • The complaint does not specify assertion of any dependent claims.

Multi-Patent Capsule: U.S. Patent No. 11,141,378

  • Patent Identification: U.S. Patent No. 11,141,378, "Lipid Formulations for Nucleic Acid Delivery," issued October 12, 2021.
  • Technology Synopsis: This patent claims a nucleic acid-lipid particle "consisting essentially of" specific components in defined molar-percent ranges, including an RNA, a cationic lipid with a protonatable tertiary amine, a mixture of phospholipid and cholesterol, and a PEG-lipid conjugate '378 Patent, cl. 1 The invention refines prior LNP compositions by using "consisting essentially of" language, which narrows the claim to formulations containing only the listed components and those that do not materially affect the invention's basic characteristics.
  • Asserted Claims: The complaint asserts at least Claim 1 Compl. ¶106
  • Accused Features: The complaint alleges that the specific lipid composition of the Accused Product meets the component and molar ratio requirements of the asserted claims Compl. ¶¶107-109

Multi-Patent Capsule: U.S. Patent No. 11,298,320

  • Patent Identification: U.S. Patent No. 11,298,320, "Liposomal Apparatus and Manufacturing Methods," issued April 12, 2022.
  • Technology Synopsis: This patent addresses the manufacturing of lipid nanoparticles by claiming an apparatus for their production. The claimed apparatus comprises reservoirs for an aqueous solution (containing a nucleic acid) and an organic lipid solution, a pump mechanism, and a mixing chamber configured to introduce the two solutions as "opposing flows at about 180° relative to each other" to instantaneously produce lipid vesicles '320 Patent, cl. 1
  • Asserted Claims: The complaint asserts at least Claim 1 Compl. ¶122
  • Accused Features: The complaint alleges that Defendants use an apparatus, described as a "T-mixer," to manufacture the Accused Product and that this apparatus infringes the claims of the '320 Patent Compl. ¶¶124-126

Multi-Patent Capsule: U.S. Patent No. 11,318,098

  • Patent Identification: U.S. Patent No. 11,318,098, "Liposomal Apparatus and Manufacturing Methods," issued May 3, 2022.
  • Technology Synopsis: This patent claims a process for producing lipid vesicles, corresponding to the apparatus claimed in the '320 patent. The claimed method involves providing aqueous and organic lipid solutions in separate reservoirs and introducing them into a mixing chamber as opposing flows at about 180° to instantaneously produce the vesicles through dilution '098 Patent, cl. 1
  • Asserted Claims: The complaint asserts at least Claim 1 Compl. ¶141
  • Accused Features: The manufacturing process used by Defendants for the Accused Product is alleged to directly infringe the claimed method Compl. ¶¶142, 144

III. The Accused Instrumentality

  • Product Identification: The Accused Product is the Pfizer-BioNTech COVID-19 vaccine, marketed under names including Comirnaty, Tozinameran, and BNT162b2 Compl. ¶8 The infringement allegations also extend to the apparatus and processes used to manufacture the vaccine Compl. ¶¶121, 140
  • Functionality and Market Context: The Accused Product is an mRNA vaccine that delivers a nucleoside-modified mRNA encoding the SARS-CoV-2 viral spike protein into human cells to elicit an immune response Compl. ¶68 The complaint alleges the vaccine uses a lipid nanoparticle delivery system composed of four specific lipids: an ionizable cationic lipid, an amphipathic lipid (DSPC), a PEG-lipid, and cholesterol Compl. ¶72 The complaint further alleges that the manufacturing process for the Accused Product employs a "T-mixer" apparatus where aqueous and organic lipid solutions are mixed Compl. ¶125 Compl. ¶126 An image from a CNN broadcast shows the exterior of the "T-mixer" allegedly used in a Pfizer production facility Compl. ¶126 The vaccine has been administered to hundreds of millions of people in the United States and has generated tens of billions of dollars in revenue for the Defendants Compl. ¶2 Compl. ¶52

IV. Analysis of Infringement Allegations

'651 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
a lipid vesicle formulation comprising: (a) a plurality of lipid vesicles, wherein each lipid vesicle comprises: a cationic lipid; an amphipathic lipid; and a polyethyleneglycol (PEG)-lipid; The Accused Product is a lipid vesicle formulation containing an ionizable cationic lipid, an amphipathic lipid (DSPC), a PEG-lipid, and cholesterol. ¶72 col. 3:53-59
and (b) messenger RNA (mRNA), The Accused Product contains a nucleoside-modified mRNA that encodes the viral spike protein of SARS-CoV-2. ¶68 col. 42:15-24
wherein at least 70% of the mRNA in the formulation is fully encapsulated in the lipid vesicles. Upon information and belief, the Accused Product's formulation has at least 70% of its mRNA fully encapsulated. ¶73 col. 24:1-9

'359 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
a nucleic acid-lipid particle comprising: (a) a nucleic acid; The Accused Product is a pharmaceutical composition of nucleic acid-lipid particles containing an mRNA that encodes the COVID-19 spike protein. ¶88 col. 2:52-54
(b) a cationic lipid comprising from 50 mol % to 65 mol % of the total lipid present in the particle; On information and belief, the Accused Product comprises a cationic lipid within this claimed molar percentage range. ¶90 col. 4:1-13
(c) a non-cationic lipid comprising a mixture of a phospholipid...from 3 mol % to 15 mol %...and cholesterol...from 30 mol % to 40 mol %...; On information and belief, the Accused Product comprises the phospholipid DSPC and cholesterol within these respective claimed molar percentage ranges. ¶90 col. 4:1-13
and (d) a conjugated lipid that inhibits aggregation of particles comprising from 0.5 mol % to 2 mol % of the total lipid present in the particle. On information and belief, the Accused Product comprises a PEG-lipid conjugate within this claimed molar percentage range. ¶90 col. 4:1-13
  • Identified Points of Contention:
    • Evidentiary Questions: For the composition patents ('651, '359, and '378), the complaint's infringement theory regarding the specific molar percentages of the lipid components rests "upon information and belief" Compl. ¶73 Compl. ¶90 Compl. ¶109 A central issue will be whether Plaintiffs can produce evidence through discovery that the final commercial vaccine formulation meets these claimed quantitative limitations.
    • Factual Questions (Apparatus/Method): For the apparatus and method patents ('320 and '098), a key factual question will be whether the "T-mixer" used by Defendants operates as claimed. This includes whether the fluid streams are introduced as "opposing flows at about 180°" and whether this process "instantaneously" produces the vesicles Compl. ¶122 Compl. ¶141 The complaint provides a diagram from a CNN interview depicting the internal workings of the T-mixer to support its allegation of opposing flows Compl. ¶127

V. Key Claim Terms for Construction

  • The Term: "cationic lipid" (from Claim 1 of the '359 Patent and other asserted patents)

  • Context and Importance: This term is central because the accused LNP formulation uses an "ionizable" cationic lipid, which is typically neutral at physiological pH but becomes positively charged in an acidic environment Compl. ¶89 The patent defines a "cationic lipid" as a species that carries a "net positive charge at a selected pH, such as physiological pH" '359 Patent, col. 13:21-24 Practitioners may focus on this term because its construction will determine whether an ionizable lipid, which is not positively charged at physiological pH, falls within the claim's scope.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The specification's use of "such as physiological pH" could be interpreted as providing a non-limiting example of a "selected pH," not a required one. The specification also describes cationic lipids with "a protonatable tertiary amine (e.g., pH titratable)" head group, which may support the inclusion of lipids that become cationic at a pH other than physiological pH '359 Patent, col. 13:35-39
    • Evidence for a Narrower Interpretation: The explicit mention of "physiological pH" as the example of a "selected pH" could be argued to limit the scope to lipids that are, in fact, cationic at that specific pH. A defendant may argue that if the patentees intended to cover lipids that are only cationic at acidic pH, they could have stated so explicitly.

  • The Term: "fully encapsulated" (from Claim 1 of the '651 Patent)

  • Context and Importance: The claim requires that "at least 70% of the mRNA... is fully encapsulated." The definition of this term is critical for determining the standard of proof for infringement. The dispute will likely center on whether "fully encapsulated" implies a strict physical containment or a more functional protection from degradation.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The patent specification describes the goal of encapsulation as protecting the nucleic acid from enzymatic degradation '651 Patent, col. 11:15-17 This could support a functional definition where a particle is "fully encapsulated" if it is sufficiently protected to resist nuclease activity in serum.
    • Evidence for a Narrower Interpretation: The plain meaning of "fully" suggests a complete physical barrier. Defendants may argue this requires the mRNA to be entirely contained within the vesicle's lipid bilayer, a higher standard than simply being resistant to degradation. The patent's use of "fully" as opposed to "partially" or simply "encapsulated" suggests a specific, high degree of containment was intended '651 Patent, col. 12:20-26

VI. Other Allegations

  • Indirect Infringement: The complaint alleges active inducement of infringement for all asserted patents. The basis for this allegation is that Defendants actively encouraged and instructed healthcare professionals and others to "use the Accused Product by administering it to millions of individuals in the United States" Compl. ¶74 Compl. ¶91 Compl. ¶110
  • Willful Infringement: Willfulness is alleged for all five patents. The allegations are based on Defendants' alleged pre-suit knowledge of the patents. This knowledge is purportedly evidenced by a 2018 license agreement between BioNTech and Genevant Compl. ¶75 Compl. ¶92, due diligence conducted by Pfizer Compl. ¶75 Compl. ¶92, and a series of notice letters sent by Plaintiffs to Defendants beginning in November 2020 Compl. ¶¶57-60 Compl. ¶75 Compl. ¶92 Compl. ¶102 Compl. ¶129

VII. Analyst's Conclusion: Key Questions for the Case

  1. A primary issue will be one of claim construction: Can the term "cationic lipid", defined in the patents with reference to a positive charge at "physiological pH," be construed to cover the "ionizable" lipid used in the Accused Product, which is neutral at physiological pH but becomes cationic in acidic environments? The resolution of this question may significantly impact the infringement analysis for the composition patents.

  2. A central evidentiary question will be one of quantitative proof: Can Plaintiffs demonstrate through discovery that the specific molar percentages of the four lipid components in the commercial Comirnaty vaccine fall within the precise ranges required by the asserted claims? The complaint's repeated reliance on "information and belief" for these values suggests this will be a critical focus of fact discovery.

  3. A key factual question for the manufacturing patents will be one of operational equivalence: Does the "T-mixer" apparatus used by Defendants for vaccine production operate in a manner that meets the specific claim limitations of "opposing flows at about 180°" and "instantaneously" forming vesicles, or is there a functional or structural difference that places it outside the claims' scope?

Loading Complaint